Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, blood tests can contribute to staging disease progression, but they work best as part of a larger picture rather than as a standalone tool. A single blood test cannot definitively stage where someone is in cognitive decline, but serial blood tests over time—combined with cognitive assessments and clinical observation—can reveal whether decline is accelerating, stabilizing, or slowing. For example, a patient might show stable cognitive test scores clinically but have rising levels of phosphorylated tau in blood, suggesting underlying disease progression that hasn’t yet manifested behaviorally. This discordance is why blood tests matter: they can catch biological changes before symptoms worsen noticeably. Blood biomarkers offer something traditional staging methods cannot: a window into brain pathology without requiring imaging or invasive procedures.
Researchers have identified several blood markers—particularly phosphorylated tau variants and amyloid-beta ratios—that correlate with brain pathology found on autopsy or detected by PET imaging. A person with early cognitive concerns might have normal scores on bedside cognitive tests yet show abnormal blood biomarker levels, suggesting preclinical disease. However, blood tests alone do not stage disease the way a radiologist stages cancer or a cardiologist stages heart failure. Blood results must be interpreted alongside clinical history, neuropsychological testing, imaging when available, and functional decline observed by family or clinicians. A positive blood test for a disease biomarker doesn’t predict when symptoms will worsen or which cognitive domains will decline first.
Table of Contents
- Which Blood Biomarkers Actually Track Disease Stage?
- What Blood Tests Miss in Disease Staging
- How Blood Tests Compare to MRI, PET Imaging, and Cognitive Testing
- Tracking Progression Over Time—Blood Tests as Serial Markers
- Standardization and Reproducibility Challenges
- Emerging Multi-Biomarker Panels and Machine Learning Models
- Blood Tests in the Context of Comprehensive Staging Protocols
- Frequently Asked Questions
Which Blood Biomarkers Actually Track Disease Stage?
The most researched blood biomarkers fall into two main categories: amyloid and tau. Phosphorylated tau (p-tau181 and p-tau217) appears in blood when tau pathology builds up in the brain, and levels tend to increase as disease progresses. Amyloid-beta 42 often decreases in blood as amyloid accumulates in the brain. The phosphorylated tau to amyloid ratio in blood has shown moderate ability to distinguish cognitively normal older adults from those with mild cognitive impairment from those with dementia in research settings. Consider a concrete example: a 68-year-old woman reports occasional memory lapses but scores normally on her Mini-Cog test. Her blood phosphorylated tau is elevated.
Two years later, her cognitive scores decline mildly, and her phosphorylated tau has risen further. The blood test progression helped confirm that her early concerns reflected genuine brain changes, not normal aging. But another person with identical blood results might never decline noticeably for a decade. The test showed biological staging, not predictive staging. Phosphorylated tau and amyloid markers correlate moderately with brain imaging findings, but correlation is not causation or certainty. Some people with “abnormal” blood biomarkers never develop cognitive symptoms, while others decline despite normal biomarker levels initially. This limitation means blood tests cannot yet replace imaging or neuropsychological testing as the gold standard for disease staging.
What Blood Tests Miss in Disease Staging
Blood biomarkers capture only parts of the disease landscape. They reflect tau and amyloid pathology but not vascular contributions, Lewy body involvement, frontotemporal degeneration markers, or other processes occurring simultaneously in an aging brain. A patient with mixed pathology—dementia driven partly by small strokes, partly by amyloid, partly by Lewy bodies—will have blood markers reflecting only the amyloid component, potentially understating or mislabeling their disease stage. A crucial limitation: blood tests are not yet standardized across laboratories. The same blood sample might return different results depending on whether it was processed with EDTA or citrate as anticoagulant, how quickly it was spun and frozen, which commercial assay was used, and whether the lab validated against a reference standard.
This measurement variability is why a blood test result from one facility might not directly compare to a result from another. A patient who moves to a different clinic or hospital may not be able to track their biomarker trajectory reliably. Additionally, blood biomarkers reflect brain changes but not functional status. Someone with stage 2 amyloid pathology by blood test might still be living independently, driving, managing finances, and working part-time—or might need 24-hour supervision. staging disease requires understanding not just the biology but how it affects daily life, something blood tests alone cannot assess.
How Blood Tests Compare to MRI, PET Imaging, and Cognitive Testing
Blood tests offer speed and accessibility compared to PET imaging, which requires radioactive tracers, specialized facilities, and cost often exceeding $3,000 to $5,000. A blood test costs $200 to $500 and can be done at a routine office visit or lab draw center. However, PET imaging shows disease topography—where in the brain pathology concentrates—while blood tests show only systemic levels. An amyloid PET scan reveals whether amyloid is accumulating primarily in the temporal lobe or broadly distributed; a blood test shows only whether amyloid is present systemically.
Cognitive testing (neuropsychology batteries) typically provides more precise staging because it captures domain-specific decline: a person might have severe memory impairment but preserved language and visuospatial skills, suggesting a specific pattern of brain involvement. Blood biomarkers are relatively crude in comparison—they cannot tell a clinician whether someone will lose language first or motor control first. The tradeoff is that cognitive testing requires 3 to 8 hours of specialized assessment and must be repeated periodically, while blood tests require only a venipuncture. Many experts now view the ideal approach as layered: start with cognitive testing and blood biomarkers (accessible, affordable, repeatable), then add MRI (to rule out stroke, tumor, atrophy patterns) or PET imaging (to confirm and localize pathology) when diagnosis remains uncertain or prognosis needs clarification.
Tracking Progression Over Time—Blood Tests as Serial Markers
Where blood tests shine is in serial monitoring. A single blood result is nearly meaningless in isolation, but comparing a patient’s phosphorylated tau from baseline to year 1 to year 2 reveals a trajectory. Rapid rises in biomarker levels may correlate with faster cognitive decline ahead, though the relationship is not perfectly predictive. A patient whose p-tau increases by 5% year-over-year might experience 5% cognitive decline, or might plateau, or might decline by 20%; individual variation is substantial. Serial blood tests allow patients and clinicians to detect changes that might otherwise be attributed to normal fluctuation or stress. A family member might notice the patient seems “off,” but standard office-based cognitive screening appears normal.
Repeat blood work showing rising tau levels validates the family’s concern and may prompt earlier intervention, imaging studies, or genetic testing for familial disease. This detective work is particularly valuable in research settings, where blood tests help researchers identify who truly is progressing and who is stable despite subjective concerns. The main limitation to serial monitoring is cost and accessibility. Repeat blood draws every 3 to 6 months, if not covered by insurance, may cost $1,000 to $3,000 per year. Some patients or families cannot sustain that expense, limiting their access to valuable progression data. Additionally, biomarker drift might represent true progression or might reflect seasonal variation, inflammation from intercurrent illness, or medication changes—all factors that complicate interpretation.
Standardization and Reproducibility Challenges
Currently, blood biomarker tests are not standardized across laboratories or countries, which means no universal “stage 2 p-tau level” exists. A result of 35 pg/mL phosphorylated tau might fall in the normal range at one laboratory and the abnormal range at another. This variability is a significant barrier to using blood tests for clinical staging in routine care, because a clinician has no universal reference to anchor interpretation. Research is underway to standardize biomarker cutoffs and establish reference ranges based on large populations, but clinical adoption remains uneven.
Some academic medical centers now offer blood biomarker testing as part of dementia workup, while rural clinics or community primary care practices may not have access to validated assays. Insurance coverage is also inconsistent; Medicare may cover advanced testing, but private insurers often do not, creating equity gaps. Importantly, a positive blood biomarker does not diagnose dementia or predict dementia onset. Many cognitively normal older adults have “abnormal” blood biomarkers yet will never meet criteria for cognitive impairment before death from other causes. This means blood tests create a new diagnostic gray zone: what does it mean if someone’s biomarkers suggest early disease but they have no cognitive symptoms? Some experts argue this knowledge is valuable for lifestyle interventions and trial enrollment, while others worry that labeling asymptomatic people with pathological biomarkers may cause unnecessary worry and lead to defensive or speculative medical workups.
Emerging Multi-Biomarker Panels and Machine Learning Models
Newer blood tests combine multiple biomarkers into panels that may better predict disease stage and prognosis than single markers alone. Tests measuring phosphorylated tau at multiple sites (p-tau181, p-tau217, p-tau396), amyloid-beta 42, neurofilament light chain (a marker of neurodegeneration), and glial fibrillary acidic protein (GFAP, a marker of glial activation) together provide a more complete picture of brain pathology. Research studies show that multi-biomarker models can outperform single markers in distinguishing disease stages.
For instance, a study combining tau, amyloid, neurofilament, and GFAP in a machine-learning model showed 85% accuracy in distinguishing cognitively normal subjects from those with mild cognitive impairment, versus 70% accuracy using p-tau181 alone. However, these models have been developed and tested in research populations, often highly educated and primarily white. Generalization to diverse populations and clinical settings is still being evaluated.
Blood Tests in the Context of Comprehensive Staging Protocols
Clinical staging requires integrating multiple data streams: the patient’s history (when memory problems started, how they’ve progressed, how they affect daily life), informant input (family members often notice decline earlier than the patient), objective cognitive testing, imaging findings when available, laboratory assessment for reversible causes (thyroid, B12, syphilis), and increasingly, blood biomarkers. Blood tests provide one piece of this puzzle—a valuable biological marker but not the whole picture. A realistic staging scenario: a 72-year-old man reports forgetfulness; his wife says he’s been repeating questions for two years and getting lost in familiar places. His Montreal Cognitive Assessment (MoCA) score is 21/30, indicating mild cognitive impairment. His MRI shows some hippocampal atrophy.
His blood phosphorylated tau is elevated at 62 pg/mL, and neurofilament is mildly elevated, suggesting active neurodegeneration. Integrated staging might conclude: early-stage cognitive impairment, likely Alzheimer disease pathologically, with imaging and biomarker evidence of progression. Blood tests contributed to this conclusion but did not determine it alone. Without the cognitive testing and imaging, the elevated blood biomarker would mean little; without the elevated biomarker, the clinical picture would be less certain. Blood tests are most useful when they confirm and refine diagnoses suggested by clinical and cognitive findings, not when they stand alone or contradict clinical reality.
Frequently Asked Questions
Can a blood test tell me if I have dementia?
No. Blood tests can detect pathological changes associated with dementia (amyloid, tau, neurodegeneration), but positive results do not diagnose dementia. Many cognitively normal people have abnormal biomarkers; some may never develop symptoms. Diagnosis requires cognitive testing, clinical assessment, and often imaging.
How often should blood tests be repeated to track disease progression?
There is no established standard interval yet. Research studies often use 6-month or annual intervals, but routine clinical practice varies. Every 1 to 2 years is common in specialty clinics. Your neurologist or geriatrician should recommend an interval based on your individual situation and whether results are changing significantly.
Are blood biomarker tests covered by insurance?
Coverage is variable and evolving. Medicare may cover some biomarker tests in specialist settings; private insurers often do not. Cost typically ranges from $200 to $500 per test. Check with your insurance and your clinician’s office about coverage before ordering.
What if my blood biomarkers are abnormal but my cognitive tests are normal?
This situation occurs in preclinical disease. Abnormal biomarkers may predict future cognitive decline, but not always. Some people with abnormal biomarkers never decline cognitively. Your clinician may recommend repeat testing in 1 to 2 years, lifestyle interventions (exercise, Mediterranean diet, cognitive stimulation), and monitoring for symptom development.
Can blood tests replace PET imaging or MRI?
Not currently. Blood tests are more accessible and affordable than PET imaging but lack the spatial information imaging provides. Blood tests complement rather than replace imaging; they are often used together for diagnosis and staging.
Which blood biomarkers are most specific for dementia staging?
Phosphorylated tau variants (p-tau181, p-tau217) and the amyloid-beta 42 to amyloid-beta 40 ratio are most studied. Neurofilament light chain and GFAP are markers of neurodegeneration and inflammation, not specific to any single disease. No single biomarker perfectly stages disease; panels of multiple markers perform better than individual tests.
